Actively Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-04-15
153
Participants Needed
20
Research Sites
227 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
CONDITIONS
Official Title
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- ECOG performance status 0-1
- Life expectancy of at least 12 weeks
- Diagnosed with advanced solid tumors refractory to standard therapies or with no standard therapy available
- For efficacy expansion: diagnosed with ovarian, breast, pancreatic, prostate cancer, or other cancers with HRR gene mutation
- At least one measurable target lesion, except for maintenance therapy
- Adequate organ and bone marrow function as required by the protocol
You will not qualify if you...
- Surgery or chemotherapy within 4 weeks before starting study treatment
- Unable to swallow or have gastrointestinal absorption problems
- Active hepatitis B, hepatitis C, or HIV infection
- Untreated or uncontrolled brain metastases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
2
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
3
Guangxi Medical University Affiliated Tumor Hosipital
Nanning, Guangxi, China, 530021
Actively Recruiting
4
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangzhou, China, 510120
Actively Recruiting
5
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081
Actively Recruiting
6
Henan Cancer Hospital
Zhengzhou, Henan, China, 450008
Actively Recruiting
7
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
8
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
9
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
10
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330209
Actively Recruiting
11
The First Hospital of Jilin University
Changchun, Jilin, China, 130021
Actively Recruiting
12
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110001
Actively Recruiting
13
Liaoning Cancer Hospital
Shenyang, Liaoning, China, 110042
Actively Recruiting
14
Qilu Hospital of Shandong University
Jinan, Shangdong, China, 250062
Actively Recruiting
15
Shandong Cancer Hospital
Jinan, Shangdong, China, 250117
Actively Recruiting
16
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China, 030001
Actively Recruiting
17
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China, 030013
Actively Recruiting
18
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China, 646099
Actively Recruiting
19
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
20
Zhejiang Cancer Hospital
Hangzhou, Zhengjiang, China, 310022
Actively Recruiting
Research Team
Q
Quanren Wang, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here